Journal List > J Korean Soc Endocrinol > v.20(4) > 1063799

TOOLS
Kim, Jee, Yoon, Chung, Lee, Cho, Kim, Chung, Min, Lee, Lee, and Kim: Efficacy of Octreotide LAR in Acromegalic Patients
Original Article
Journal of Korean Society of Endocrinology

Journal of Korean Society of Endocrinology 2005; 20(4): 344-352.

Published online: 31 August 2005

DOI: https://doi.org/10.3803/jkes.2005.20.4.344

Efficacy of Octreotide LAR in Acromegalic Patients

Ji Youn Kim, Jae Hwan Jee, Chan Ho Yoon, Yun Jae Chung, Byung Wan Lee, Gun Yong Cho, Sang Young Kim, Jae Hoon Chung, Yong-Ki Min, Myung-Shik Lee, Moon-Kyu Lee, Kwang-Won Kim

Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Received 3 February 2005       Accepted 3 June 2005

Copyright © 2005 Korean Endocrine Society

Abstract

Background

Octreotide (OC)-LAR is a long-acting preparation of octreotide which has been effectively used to suppress GH/IGF-1 hypersecretion in acromegalic patients. The clinical response, biochemical outcomes, and safety of OC-LAR were evaluated in 27 active acromegalic patients.

Method

27 patients with an active disease status (according to the clinical picture, GH >5 µg/L and elevated age-matched IGF-1), and previously treated with bromocriptine after surgery, comprised the study population. OC-LAR was given (20 mg, i.m., every 4 week for 3 injections, then the doses were titrated individually) and the acromegalic symptoms and adverse reactions recorded. The serum levels of GH and IGF-1 were evaluated every 12 week. The acromegalic symptoms including headache, fatigue and arthralgia, improved in all patients.

Results

Gastrointestinal side effects were transient and mild. The levels of GH significantly decreased, from 8.9 ± 3.5 to 2.9 ± 2.2 µg/L at 12 weeks (P< 0.001, vs. baseline), to 2.9 ± 2.1 µg/L after 24 weeks (P< 0.001) and to 2.5 ± 1.3 µg/L at 48 weeks (P< 0.001). The levels of IGF-1 significantly decreased, from 753.7 ± 213.6 to 429.7 ± 253.4 µg/L at 12 weeks (P< 0.001, vs. at baseline), to 405.7 ± 213.3 µg/L at 24 weeks (P< 0.001) and to 348.9 ± 144.7 µg/L at 48 weeks (P<0.001). The safelevel of GH is less than 2.5 µg/L and normal age-matched IGF-1 levels were achieved in 63 and 52% of the patients, respectively.

Conclusion

Octreotide-LAR was well tolerated and effective as an adjuvant treatment in lowering the levels of GH and IGF-1 in active acromegalic patients

Keywords: Octreotide-LAR (OC-LAR), Acromegaly, Somatostatin analogue

Figures and Tables

Fig. 1
GH (a) and IGF-1 (b) levels (mean ± SD) during treatment. GH and IGF-1 levels decreased significantly at 12 weeks and progressively suppressed. *P< 0.01 vs. basal level
jkse-20-344-g001
Fig. 2
Kaplan-Meier analysis for achievement of safe GH levels and IGF-1 normalization. The rate of safe GH (<2.5 µg/L) and IGF-1 normalization were 78% and 88% at 48 weeks
jkse-20-344-g002
Fig. 3
Individual GH level (a) and IGF-1 levels (b) at basal (upper line) and final (lower line) on OC-LAR
jkse-20-344-g003
Fig. 4
Correlation between the responses of GH and IGF-1 on OC-LAR. There is positive correlation between the suppression (%) of GH and IFG-1 during treatment (r=0.402, P<0.001)
jkse-20-344-g004
Table 1
The Baseline Characteristics of the Patients
jkse-20-344-i001

Values are the mean ± SD

Table 2
Overall Outcome of OC-LAR on GH and IGF-1
jkse-20-344-i002
Table 3
The Characteristics of Two Groups in Response to OC-LAR
jkse-20-344-i003

Values are the mean ± SD. The good response defined as GH <2.5 µg/L and normal age-matched IGF-1 levels at the latest visit after treatment with OC-LAR. Suppression (%) was calculated with equation as follows: (basal level level at 12 weeks) / basal level ×100

Table 4
The Multivariate Regression with Good Response on OC-LAR
jkse-20-344-i004

The good response defined as GH <2.5 µg/L and normal age-matched IGF-1 levels at the latest visit after treatment with OC-LAR.

References

1. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med. 1970. 39:1–16.
2. Growth Hormone Research Society. Pituitary Society. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab. 2004. 89:3099–3102.
3. Melmed S. Octreotide stimulates insulin-like growth factor binding protein-1: a novel mechanism of drug action on acromegaly. Semin Oncol. 1994. 21:65–69.
4. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994. 41:95–102.
5. Melmed S. Acromegaly. N Engl J Med. 1990. 322:966–977.
6. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab. 1998. 83:2646–2652.
7. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000. 85:526–529.
8. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 1998. 89:353–358.
9. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab. 1995. 80:3267–3272.
10. Van der Lely AJ, de Herder WW, Lamberts SW. The role of radiotherapy in acromegaly. J Clin Endocrinol Metab. 1997. 82:3185–3186.
11. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992. 21:713–735.
12. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998. 83:374–378.
13. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf). 2002. 56:65–71.
14. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab. 2002. 87:4554–4563.
15. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001. 86:2779–2786.
16. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998. 83:3419–3426.
17. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon. Qjm. 1999. 92:741–745.
18. Peacey SR, Shalet SM. Growth hormone pulsatility in acromegaly following radiotherapy. Pituitary. 1999. 2:63–69.
19. Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio M. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab. 2003. 88:3105–3112.
20. Al-Maskari M, Gebbie J, Kendall-Taylor P. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly . Clin Endocrinol (Oxf). 1996. 45:415–421.
21. Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf). 1999. 51:275–280.
22. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Dru. s. 1997. 53:681–699.
23. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996. 334:246–254.
24. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003. 88:3090–3098.
25. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 1988. 9:417–436.
26. Lamberts SW, Zweens M, Klijn JG, van Vroonhoven CC, Stefanko SZ, Del Pozo E. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Clin Endocrinol (Oxf). 1986. 25:201–212.
27. Van der Lely AJ, Harris AG, Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf). 1992. 37:181–185.
28. Acromegaly Therapy Consensus Development Panel. Consensus statement: Benefits versus risks of medical therapy for acromegaly. Am J Med. 1994. 97:468–473.
29. Montini M, Gianola D, Pagani MD, Pedroncelli A, Caldara R, Gherardi F, Bonelli M, Lancranjan I, Pagani G. Cholelithiasis and acromegaly: therapeutic strategies. Clin Endocrinol (Oxf). 1994. 40:401–406.
30. Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JA. Gallstones during octreotide therapy. Metabolism. 1992. 41:22–33.
31. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 1997. 82:18–22.
33. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001. 358:1754–1759.
34. Wagenaar AH, Harris AG, Van der Lely AJ, Lamberts SW. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinol (Copenh). 1991. 125:637–642.
35. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab. 1998. 83:3808–3816.
36. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab. 2002. 87:3537–3542.
TOOLS
Similar articles